Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
Condition: Splenic Marginal Zone Lymphoma · Sponsor: International Extranodal Lymphoma Study Group (IELSG)
About this study
The goal of this clinical trial is to compare the efficacy and tolerability of the combination of two medicinal products, rituximab, and zanubrutinib, compared to rituximab monotherapy in patients with Splenic Marginal Zone Lymphoma (SMZL), previously untreated and who need systemic treatment. The main questions it aims to answer are: * Is the combination rituximab and zanubrutinib a more effective therapy than rituximab monotherapy? * Is the combination therapy, rituximab and zanubrutinib, well tolerated? Study participants will be put into one of the two treatment groups (rituximab and zanubrutinib or rituximab alone) for a maximum of two years and will undergo regular visits until three years from treatment start.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (49)
| Medical University of Vienna | Vienna, Austria | — |
| Institut Bergonié | Bordeaux, France | — |
| CHU de Grenoble | Grenoble, France | — |
| Hôpital Saint Louis | Paris, France | — |
| Hôpital Lyon-Sud | Pierre-Bénite, France | — |
| CHRU Nancy Brabois | Vandœuvre-lès-Nancy, France | — |
| IRCCS Istituto Tumori Giovanni Paolo II | Bari, Italy | — |
| IRCCS AOU di Bologna | Bologna, Italy | — |
| ASST Spedali Civili di Brescia | Brescia, Italy | — |
| A.O.U. Policlinico G. Rodolico-S. Marco | Catania, Italy | — |
| IRCCS IRST Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" | Meldola, Italy | — |
| Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milan, Italy | — |
+ 37 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05735834